Manufacturing functional cells from induced pluripotent stem cells (iPSC) with consistent quality and scale is a crucial, yet challenging step to effectively integrate iPSC technology in drug discovery, regenerative medicine or tissue engineering. iPSCs possess unique advantages, including patient specificity, self-renewal, and the remarkable ability to differentiate into any cell type. However, the intricate process of iPSC differentiation, influenced by various factors, poses obstacles to achieving standardization, consistency and adoption.
With more than a decade of iPSC innovation, Ncardia has expertise in standardizing procedures for multiple cell lineages, including cardiac and neuronal. This knowledge has been expanded to endodermal derivatives, a complex iPSC lineage. This built expertise enables Ncardia to offer flexible and robust procedures for any cell type, regardless of the iPSC line used.
In the example described in this case study, Ncardia's expert team develops scalable procedures for differentiating the four main cell types of human lungs to deliver pure and functional cells for various applications such as disease modeling, drug discovery, regenerative medicine and tissue engineering.
This case study describes the Ncardia approach to overcome major challenges in iPSC manufacturing with a focus on scalability, data-driven decision-making and time efficiency.
Download the case study and discover the benefits:
-
High quality end-product
-
Reproducible and Consistent
-
Success in shorter time